TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07664553: A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin (Eluminate

Sponsor: AstraZeneca · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$5,515,848

Rescue Site Savings

+$3,630,088

Unlock Full NCT07664553 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07664553 Rescue Dossier →